Mereo BioPharma Group (MREO)
Mereo BioPharma Statistics
Share Statistics
Mereo BioPharma has 155.15M shares outstanding. The number of shares has increased by 453.03% in one year.
| Shares Outstanding | 155.15M |
| Shares Change (YoY) | 453.03% |
| Shares Change (QoQ) | 401.33% |
| Owned by Institutions (%) | 14.96% |
| Shares Floating | 142.66M |
| Failed to Deliver (FTD) Shares | 1.54K |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 7.2M, so 4.65% of the outstanding shares have been sold short.
| Short Interest | 7.2M |
| Short % of Shares Out | 4.65% |
| Short % of Float | 5.07% |
| Short Ratio (days to cover) | 5.49 |
Valuation Ratios
The PE ratio is -11.97 and the forward PE ratio is -129.45. Mereo BioPharma's PEG ratio is 0.12.
| PE Ratio | -11.97 |
| Forward PE | -129.45 |
| PS Ratio | 0 |
| Forward PS | 1.4 |
| PB Ratio | 8.49 |
| P/FCF Ratio | -15.77 |
| PEG Ratio | 0.12 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Mereo BioPharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.4, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.4 |
| Quick Ratio | 5.4 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.03 |
| Interest Coverage | 34.57 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.2M |
| Employee Count | 36 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -35.8% in the last 52 weeks. The beta is 0.98, so Mereo BioPharma's price volatility has been higher than the market average.
| Beta | 0.98 |
| 52-Week Price Change | -35.8% |
| 50-Day Moving Average | 2.69 |
| 200-Day Moving Average | 3.65 |
| Relative Strength Index (RSI) | 31.92 |
| Average Volume (20 Days) | 1.26M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -47.36M |
| Net Income | -43.25M |
| EBITDA | -47.36M |
| EBIT | -44.62M |
| Earnings Per Share (EPS) | -0.06 |
Balance Sheet
The company has 69.8M in cash and 894K in debt, giving a net cash position of 68.91M.
| Cash & Cash Equivalents | 69.8M |
| Total Debt | 894K |
| Net Cash | 68.91M |
| Retained Earnings | -462.88M |
| Total Assets | 76.39M |
| Working Capital | 60.91M |
Cash Flow
In the last 12 months, operating cash flow was -32.83M and capital expenditures 0, giving a free cash flow of -32.83M.
| Operating Cash Flow | -32.83M |
| Capital Expenditures | 0 |
| Free Cash Flow | -32.83M |
| FCF Per Share | -0.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MREO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MREO is $7, which is 222.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 222.6% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 4.09 |
| Piotroski F-Score | 2 |